Buy CBD Cannabidiol CAS 13956-29-1 Online at Cheap Prices at PurelyChem!
CBD Cannabidiol (CAS 13956-29-1) is a phytocannabinoid that is used as analytical reference material. Cannabidiol, unlike 9-THC, is not psychoactive. This product is designed for scientific and research purposes. You can easily buy CBD Cannabidiol (CAS 13956-29-1) online at PurelyChem at the best prices available.
CBD Cannabidiol (CAS 13956-29-1) for sale is the non-psychotropic component of Cannabis sativa glandular hairs. It has anticonvulsant, sedative, hypnotic, antipsychotic, and anti-inflammatory activities, and neuroprotective qualities. It is a significant phytocannabinoid that binds to a number of physiological targets of the endocannabinoid system in the body, accounting for up to 40% of the Cannabis plant’s extract.
CBD Cannabidiol (CAS 13956-29-1) online has shown potential as a therapeutic and pharmaceutical medication target, while the specific medicinal consequences are still being explored. CBD has demonstrated analgesic, anticonvulsant, muscle relaxant, anxiolytic, antipsychotic, neuroprotective, anti-inflammatory, and antioxidant properties, among other currently researched uses.
Cannabidiol was originally extracted from marijuana in the late 1930s, but its structure and stereochemistry were only discovered in 1963. CBD pharmacology research began in the 1970s, with the first significant findings describing its hypnotic and anticonvulsant characteristics appearing in 1981. A substantial body of pharmacological effects has been demonstrated since then, both in preclinical and clinical research.
- This product was built and tested by ISO/IEC 17025:2005 and ISO Guide 34:2009 standards.
- The purpose of this product is to serve as an analytical reference standard.
- At accredited institutes, the bulk material is available for academic research.
Sativex, a combination of cannabidiol and delta-9-tetrahydrocannabinol, was used as an adjunctive treatment for symptomatic relief of spasticity in adults with multiple sclerosis who had not responded adequately to other therapies and showed meaningful improvement during an initial trial of therapy.